Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Randomised, Open-label, Multicentre, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib Following Single 400 mg Doses of the Capsule Formulation in Patients With Advanced Solid Tumours.

NCT01851265 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01851265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01851265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Randomised, Open-label, Multicentre, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib Following Single 400 mg Doses of the Capsule Formulation in Patients With Advanced Solid Tumours.
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
July 4, 2013
Completion date
June 6, 2017
Enrollment
32 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours